Presentation to Highlight Genprex’s Study of Reqorsa® Gene Therapy in Combination with Tecentriq® for the Treatment of Extensive Stage Small Cell Lung Cancer AUSTIN, Texas — (May 29, 2025) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it […]
Novel Gene Therapy is Addressing Both Type 1 and Type 2 Diabetes AUSTIN, Texas — (May 28, 2025) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that its research collaborators presented positive preclinical data and research from studies of GPX-002, […]
Advances Relationship and Collaboration with the University of Pittsburgh of the Commonwealth System of Higher Education AUSTIN, Texas — (May 7, 2025) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that following the recent completion of its two-year Sponsored […]
License Expands Genprex’s Portfolio of Oncology Gene Therapy Technologies AUSTIN, Texas — (May 6, 2025) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive patent license agreement with UTHealth Houston granting Genprex exclusivity and […]